Postmarketing surveillance of new drugs: I. Review of objectives and methodology.
作者信息
Wardell W M, Tsianco M C, Anavekar S N, Davis H T
出版信息
J Clin Pharmacol. 1979 Feb-Mar;19(2-3):85-94. doi: 10.1002/j.1552-4604.1979.tb02464.x.
Abstract
摘要
相似文献
1
Postmarketing surveillance of new drugs: I. Review of objectives and methodology.新药上市后监测：I. 目标与方法综述。
J Clin Pharmacol. 1979 Feb-Mar;19(2-3):85-94. doi: 10.1002/j.1552-4604.1979.tb02464.x.
2
Discovering adverse drug reactions.
JAMA. 1983;249(16):2224-5.
3
Post-marketing surveillance of prescription drug safety: past, present, and future.处方药安全性的上市后监测：过去、现在与未来。
J Leg Med. 2013;34(2):193-213. doi: 10.1080/01947648.2013.800797.
4
Can postmarketing surveillance help to effect optimal drug therapy?上市后监测能否有助于实现最佳药物治疗？
JAMA. 1979 Nov 30;242(22):2420-2.
5
Trends in boxed warnings and withdrawals for novel therapeutic drugs, 1996 through 2012.1996年至2012年新型治疗药物的盒装警示及撤市趋势。
JAMA Intern Med. 2014 Oct;174(10):1704-5. doi: 10.1001/jamainternmed.2014.4854.
6
The Food and Drug Administration Amendments Act of 2007: drug safety and health-system pharmacy implications: introduction.2007年《食品药品管理局修订法案》：药品安全及医疗系统药房的影响：引言
Am J Health Syst Pharm. 2009 Dec 15;66(24 Suppl 7):S2-3. doi: 10.2146/ajhp090459.
7
Assessing Drug Safety in Children - The Role of Real-World Data.评估儿童用药安全性——真实世界数据的作用。
N Engl J Med. 2018 Jun 7;378(23):2155-2157. doi: 10.1056/NEJMp1802197.
8
Postmarketing surveillance of new drugs: II. Case studies.新药上市后监测：II. 案例研究。
J Clin Pharmacol. 1979 Apr;19(4):169-84. doi: 10.1002/j.1552-4604.1979.tb01649.x.
9
Legal perspectives in causality assessment.因果关系评估中的法律视角。
Drug Inf J. 1984;18(3-4):211-7. doi: 10.1177/009286158401800304.
10
A prescription for monitoring drugs.一份监测药物的处方。
Science. 1980 Feb 22;207(4433):853-5. doi: 10.1126/science.7355265.
引用本文的文献
1
Monitoring adverse drug reactions: a preliminary study.监测药物不良反应：初步研究。
Can Fam Physician. 1981 Aug;27:1235-8.
2
A survey of adverse drug reactions in family practice.家庭医疗中的药物不良反应调查。
Can Fam Physician. 1984 Jan;30:81-4.
3
Pharmacovigilance: methods, recent developments and future perspectives.药物警戒：方法、最新进展与未来展望
Eur J Clin Pharmacol. 2008 Aug;64(8):743-52. doi: 10.1007/s00228-008-0475-9. Epub 2008 Jun 4.
4
[Drug safety: activities of the manufacturer].
Soz Praventivmed. 1980 Mar;25(1-2):14-7. doi: 10.1007/BF02075063.
5
Assessment of adverse drug reactions in psychiatric hospitals.精神病医院中药物不良反应的评估。
Eur J Clin Pharmacol. 1984;26(6):727-34. doi: 10.1007/BF00541933.
6
The role of record linkage in post-marketing drug surveillance.记录链接在上市后药品监测中的作用。
Br J Clin Pharmacol. 1986;22 Suppl 1(Suppl 1):77S-82S. doi: 10.1111/j.1365-2125.1986.tb02987.x.
7
Adverse effects of hypolipidaemic drugs.降血脂药物的不良反应。
Med Toxicol. 1987 Jan-Feb;2(1):10-32. doi: 10.1007/BF03259858.
8
New approaches to postmarketing surveillance.上市后监测的新方法。
Psychopharmacology (Berl). 1986;90(3):347-50. doi: 10.1007/BF00179189.
Zotero 插件